<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148992</url>
  </required_header>
  <id_info>
    <org_study_id>Lofexidine-0001</org_study_id>
    <nct_id>NCT01148992</nct_id>
  </id_info>
  <brief_title>Interactions Between Intravenous (IV) Cocaine and Lofexidine</brief_title>
  <official_title>Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Lofexidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess potential interactions between intravenous (IV)
      cocaine and treatment with lofexidine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the safety of daily oral lofexidine alone and concurrent with IV cocaine
      infusions of 20 mg and 40 mg in cocaine-experienced, non-opiate-addicted volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event and Cardiovascular Response</measure>
    <time_frame>Daily, up to 9 days</time_frame>
    <description>Adverse Events will measured during follow-up at weeks 14-21</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Parameter of Cocaine and Benzoylecgonine (BE)</measure>
    <time_frame>Daily, up to 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Lofexidine</measure>
    <time_frame>Daily, up to 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>Daily, up to 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Substance Abuse Craving Scale (BSCA)</measure>
    <time_frame>Daily, up to 9 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cocaine Related Disorders</condition>
  <arm_group>
    <arm_group_label>Lofexidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine</intervention_name>
    <description>0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg</description>
    <arm_group_label>Lofexidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be volunteers who meet Diagnostic and Statistical Manual of Mental Disorders Fourth
             Edition (DSM-IV) criteria for cocaine abuse or dependence and are non-treatment
             seeking at the time of the study.

          -  Be between 18 and 50 years of age, inclusive.

          -  Be currently use cocaine. Use must be confirmed by a positive urine test for cocaine
             metabolites once within the outpatient screening period.

          -  Be able to verbalize understanding of the consent form and provide written informed
             consent.

          -  Females must have a negative pregnancy test within 72 hours prior to receiving the
             first infusion of cocaine. They must also be postmenopausal, have had a hysterectomy,
             been sterilized, or agree to use one of the following methods of birth control:

               -  diaphragm and condom by partner

               -  intrauterine device (that does not contain progesterone) and condom by partner

               -  sponge and condom by partner

               -  complete abstinence from sexual intercourse

        Note: Oral contraceptives, Depo-Provera, Norplant, Patch, and intrauterine progesterone
        contraceptive system are not allowed.

        Exclusion Criteria:

          -  Please contact site for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Lofexidine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

